• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Blue Water Acquisition Corp.

    9/17/21 4:15:45 PM ET
    $BLUWU
    Business Services
    Finance
    Get the next $BLUWU alert in real time by email
    SC 13G 1 tm2127868d1_sc13g.htm SC 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE
    COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.       )*

     

    CLARUS THERAPEUTICS HOLDINGS, INC.
    (Name of Issuer)
     
    Shares of Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    18271L107
    (CUSIP Number)
     
    September 9, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 1 of 7

     

      1. Names of Reporting Persons
    FFI Fund Ltd.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,627,795 shares of Common Stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,627,795 shares of Common Stock

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,627,795 shares of Common Stock
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    7.5%
     
      12. Type of Reporting Person (See Instructions)
    OO

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 2 of 7

     

      1. Names of Reporting Persons
    FYI Ltd.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    312,179 shares of Common Stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    312,179 shares of Common Stock

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    312,179 shares of Common Stock
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    1.4%
     
      12. Type of Reporting Person (See Instructions)
    OO

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 3 of 7

     

      1. Names of Reporting Persons
    Olifant Fund, Ltd.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    289,881 shares of Common Stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    289,881 shares of Common Stock

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    289,881 shares of Common Stock
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    1.3%
     
      12. Type of Reporting Person (See Instructions)
    OO

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 4 of 7

     

      1. Names of Reporting Persons
    Bracebridge Capital, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware

     

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    2,229,855 shares of Common Stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    2,229,855 shares of Common Stock

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    2,229,855 shares of Common Stock
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    10.3%
     
      12. Type of Reporting Person (See Instructions)
    OO, IA

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 5 of 7

     

    Item 1.

     

    (a)Name of Issuer:

     

    Clarus Therapeutics Holdings, Inc. (the “Issuer”).

     

    (b)Address of the Issuer’s Principal Executive Offices:

     

    555 Skokie Boulevard, Suite 340, Northbrook, IL 60062

     

    Item 2.

     

    (a)Name of Person Filing:

     

    This joint statement on Schedule 13G is being filed by FFI Fund Ltd. (“FFI”), FYI Ltd. (“FYI”), Olifant Fund, Ltd. (“Olifant” and collectively with FFI and FYI, the “Funds”), and Bracebridge Capital, LLC (the “Investment Manager”), who are collectively referred to as the “Reporting Persons.”  The Investment Manager is the investment manager of each of the Funds.  The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 99.1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.

     

    (b)Address of Principal Business Office:

     

    The principal business office of the Reporting Persons with respect to the Shares reported hereunder is 888 Boylston Street, 15th Floor, Boston, Massachusetts 02199.

     

    (c)Citizenship:

     

    The Investment Manager is a Delaware limited liability company.  Each of the Funds is a Cayman Islands exempted company.

     

    (d)Title and Class of Securities:

     

    Shares of common stock, $0.0001 par value per share, of the Issuer (the “Shares”).

     

    (e)CUSIP Number:

     

    18271L107.

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    N/A.

     

    Item 4.Ownership:

     

    (a).          Amount beneficially owned:

     

    As of the date hereof, the Reporting Persons, in the aggregate, may be deemed to beneficially own 2,229,855 Shares, which amount includes (i) the 1,627,795 Shares beneficially owned by FFI, (ii) the 312,179 Shares beneficially owned by FYI, and (iii) the 289,881 Shares beneficially owned by Olifant.

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 6 of 7

     

    (b).          Percent of class:

     

    As of the date hereof, the Reporting Persons, in the aggregate, may be deemed the beneficial owner of approximately 10.3% of Shares outstanding, which amount includes (i) 7.5% of Shares outstanding beneficially owned by FFI, (ii) 1.4% of Shares outstanding beneficially owned by FYI, and (iii) 1.3% of Shares outstanding beneficially owned by Olifant. The percentage of Shares beneficially owned by each Reporting Person is based on a total of 21,725,817 Shares outstanding as of September 10, 2021, as reported in the Issuer’s current report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2021.

     

    (c).          Number of shares as to which such person has:

     

    FFI:

    (i)             Sole power to vote or to direct the vote: 0

    (ii)            Shared power to vote or to direct the vote: 1,627,795

    (iii)           Sole power to dispose or to direct the disposition of: 0

    (iv)           Shared power to dispose or to direct the disposition of: 1,627,795

     

    FYI:

    (i)             Sole power to vote or to direct the vote: 0

    (ii)            Shared power to vote or to direct the vote: 312,179

    (iii)           Sole power to dispose or to direct the disposition of: 0

    (iv)           Shared power to dispose or to direct the disposition of: 312,179

     

    Olifant:

    (i)             Sole power to vote or to direct the vote: 0

    (ii)            Shared power to vote or to direct the vote: 289,881

    (iii)           Sole power to dispose or to direct the disposition of: 0

    (iv)           Shared power to dispose or to direct the disposition of: 289,881

     

    The Investment Manager:

    (i)             Sole power to vote or to direct the vote: 0

    (ii)            Shared power to vote or to direct the vote: 2,229,855

    (iii)           Sole power to dispose or to direct the disposition of: 0

    (iv)           Shared power to dispose or to direct the disposition of: 2,229,855

     

    Each of the Funds has the power to vote and dispose of the Shares beneficially owned by such entity (as described above), and each of the Funds expressly disclaims beneficial ownership of any Shares not owned directly by it except to the extent of any pecuniary interest therein. The Investment Manager, as the investment manager of each of the Funds, has the authority to vote and dispose of all of the Shares reported in this Schedule 13G, but expressly disclaims beneficial ownership of any Shares not owned directly by it except to the extent of its pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    N/A.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

     

    N/A.

     

     

     

     

    CUSIP No. 18271L107 Schedule 13G Page 7 of 7

     

    Item 8.Identification and Classification of Members of the Group:

     

    N/A.

     

    Item 9.Notice of Dissolution of Group:

     

    N/A.

     

    Item 10.Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    September 17, 2021

     

      BRACEBRIDGE CAPITAL, LLC

     

      BY: /s/ Gabriel Sunshine

      Name: Gabriel Sunshine
      Title: Authorized Signatory

     

      FFI FUND LTD.

     

      BY: /s/ Gabriel Sunshine

      Name: Gabriel Sunshine
      Title: Authorized Signatory

     

      FYI LTD.

     

      BY: /s/ Gabriel Sunshine

      Name: Gabriel Sunshine
      Title: Authorized Signatory

     

      OLIFANT FUND, LTD.

     

      BY: /s/ Gabriel Sunshine

      Name: Gabriel Sunshine
      Title: Authorized Signatory

     

    [Signature Page to Schedule 13G]

     

     

     

     

    EXHIBIT LIST

     

    Exhibit 99.1   Joint Filing Agreement, by and among the Reporting Persons, dated as of September 17, 2021.

     

     

     

    Get the next $BLUWU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUWU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLUWU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Blue Water Acquisition Corp. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      10/8/21 4:24:24 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13G filed by Blue Water Acquisition Corp.

      SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/24/21 6:06:39 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13D filed by Blue Water Acquisition Corp.

      SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/21/21 4:18:31 PM ET
      $BLUWU
      Business Services
      Finance

    $BLUWU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:09:50 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3 filed by new insider H.I.G. Ventures - Clarus, Llc

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:07:54 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3: New insider Cbc Spvi Ltd claimed ownership of 3,602,287 units of Common Stock

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      9/24/21 6:05:09 AM ET
      $BLUWU
      Business Services
      Finance

    $BLUWU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blue Water Acquisition Corp. III Announces Closing of Upsized $253 Million Initial Public Offering

      GREENWICH, Conn., June 11, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company") (NASDAQ:BLUWU), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the closing of its upsized initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option, at an offering price of $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company'

      6/11/25 1:24:00 PM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering

      GREENWICH, Conn., June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the upsized pricing of its initial public offering of 22,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units are expected to trade on The Nasdaq Global Market ("Nasdaq")under the ticker symbo

      6/10/25 6:00:00 AM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

      GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o

      8/27/21 12:58:37 PM ET
      $BLUW
      $BLUWU
      Business Services
      Finance

    $BLUWU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Blue Water Acquisition Corp.

      EFFECT - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/8/21 12:15:18 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 424B3 filed by Blue Water Acquisition Corp.

      424B3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/7/21 5:07:36 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form S-1 filed by Blue Water Acquisition Corp.

      S-1 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      9/30/21 4:07:33 PM ET
      $BLUWU
      Business Services
      Finance